Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2026)
Maxcyte's (MXCT) quarterly Asset Writedowns and Impairment came in at $197000.0 in Q1 2026, up 203.08% year-on-year from $65000.0 in Q1 2025, and down 69.55% on a QoQ basis from $647000.0 in Q4 2025.
Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Maxcyte (MXCT) has 4 years of Asset Writedowns and Impairment data on file, last reported at $197000.0 in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 203.08% year-over-year to $197000.0 in Q1 2026; TTM through Mar 2026 was $808000.0, a 514.36% increase from a year earlier, with the FY2025 full-year figure at $676000.0, up 620.0% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $197000.0, down from $647000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for MXCT reached as high as $647000.0 in Q4 2025 and fell as low as -$267000.0 in Q3 2024.
- Historically, Asset Writedowns and Impairment has averaged $68400.0 across 4 years, with a median of $36000.0 in 2024.
- Across the five-year window, Asset Writedowns and Impairment sank 2866.67% in 2024 and soared 1328.57% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at -$50000.0 in 2023, then tumbled by 434.0% to -$267000.0 in 2024, then soared by 342.32% to $647000.0 in 2025, then slumped by 69.55% to $197000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $197000.0 in Q1 2026, $647000.0 in Q4 2025, and -$136000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.85 Bn | 176.55 Bn | 6.27 Bn |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn |
| 3 | Medtronic | 108.55 Bn | 99.33 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.56 Bn | 67.10 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.15 Bn | 25.87 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - |
| 9 | Koninklijke Philips | 24.75 Bn | 21.63 Bn | 2.07 Bn |
| 10 | Maxcyte | 111.68 Mn | 111.68 Mn | 8.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197,000.00 |
| Mar 31, 2026 | 197,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | -136,000.00 |
| Sep 30, 2025 | -136,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Sep 30, 2024 | -267,000.00 |
| Sep 30, 2024 | -267,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 130,000.00 |
| Mar 31, 2024 | 130,000.00 |
| Dec 31, 2023 | -50,000.00 |
| Dec 31, 2023 | -50,000.00 |
| Sep 30, 2023 | -9,000.00 |
| Sep 30, 2023 | -9,000.00 |